이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aclarion 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Brent Ness

최고 경영자

US$300.0k

총 보상

CEO 급여 비율	100.0%
CEO 임기	3yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Brent Ness 의 보수는 Aclarion 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$6m
Mar 31 2024	n/a	n/a	-US$6m
Dec 31 2023	US$300k	US$300k	-US$5m
Sep 30 2023	n/a	n/a	-US$5m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$7m
Dec 31 2022	US$509k	US$300k	-US$7m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$526k	US$100k	-US$6m

보상 대 시장: Brent 의 총 보상 ($USD 300.00K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 683.56K ).

보상과 수익: Brent 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Brent Ness (57 yo)

3yrs

테뉴어

US$300,000

보상

Mr. Brent Ness has been President of Aclarion, Inc. (fka Nocimed, Inc.) since October 1, 2021 and its Chief Executive Officer & Director since September 15, 2021. From December 2019 to April 2021, Mr. Ness...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jeffrey Thramann	Executive Chairman	4yrs	US$300.00k	0% $ 0
Brent Ness	CEO, President & Director	3yrs	US$300.00k	0.014% $ 225.2
John Lorbiecki	Chief Financial Officer	2.9yrs	US$225.00k	0.015% $ 246.1
Ryan Bond	Chief Strategy Officer	3yrs	US$200.00k	0.014% $ 219.7

3.0yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: ACON 의 관리팀은 경험 ( 2.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jeffrey Thramann	Executive Chairman	4yrs	US$300.00k	0% $ 0
Brent Ness	CEO, President & Director	3yrs	US$300.00k	0.014% $ 225.2
William Wesemann	Lead Independent Director	8.7yrs	US$40.00k	0.036% $ 579.5
Jeffrey Lotz	Member of Scientific Advisory Board	no data	US$12.86k	데이터 없음
Stephen Deitsch	Independent Director	2.4yrs	US$45.00k	0% $ 0
Scott Breidbart	Independent Director	2.4yrs	US$40.00k	0% $ 0
Robert Eastlack	Member of Medical Advisory Board	no data	US$14.77k	데이터 없음
David Neal	Director	8yrs	US$25.00k	0.13% $ 2.0k
Amanda Williams	Independent Director	2.4yrs	US$35.00k	0% $ 0
Lawrence Tannenbaum	Member of Medical Advisory Board	no data	US$10.40k	데이터 없음

3.0yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: ACON 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Aclarion 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

High number of new and inexperienced directors

Aclarion, Inc. George Frey MD as Key Opinion Leader

Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

High number of new directors

Recent updates

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Aclarion, Inc. has filed a Follow-on Equity Offering in the amount of $1.075 million.

Aclarion Launches Surgeon Partnership to Apply Nociscan's Ai Technology to Personal Injury and Workers Compensation Market

Aclarion Receives Non-Compliance Letter from Nasdaq Due to Non-Compliance with the Nasdaq Minimum Stockholders’ Equity Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.44 loss per share (vs US$2.39 loss in 1Q 2023)

Aclarion Receives Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Aclarion, Inc. has completed a Composite Units Offering in the amount of $3.0015 million.

Full year 2023 earnings released: US$8.82 loss per share (vs US$19.61 loss in FY 2022)

Aclarion Announces Updated Product Release That Expands Mri Scanner Access for Nociscan Solution

New major risk - Shareholder dilution

Aclarion, Inc. announced that it has received $0.25 million in funding

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.21 loss in 3Q 2022)

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Nasdaq Staff Determines to Delist the Aclarion Common Stock from Nasdaq, Unless the Company Timely Requests an Appeal of the Staff’s Determination to A Hearings Panel

Nasdaq Confirms Aclarion Regains Compliance with Rule 5250(c)(1) Regarding Filing of 10-Q Report

Aclarion Announces Update on Non-Compliance Notice from Nasdaq Regarding Late Filing of 10-Q Report

High number of new and inexperienced directors

Aclarion Receives Non-Compliance Notice From Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aclarion, Inc. Receives Nasdaq Notice Regarding Late Filing of 10-Q Report

Aclarion, Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.25 loss per share (vs US$6.58 loss in FY 2021)

Aclarion, Inc. George Frey MD as Key Opinion Leader

Aclarion, Inc. Receives a Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

High number of new directors

Aclarion, Inc.'s Nociscan Selected for Inclusion in Pivotal National Institutes of Health Study for Low Back Pain

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings released: US$1.35 loss per share (vs US$0.81 loss in 1Q 2021)

Director recently bought US$150k worth of stock

High number of new directors

Aclarion, Inc. has completed an IPO in the amount of $9.41775 million.

Aclarion, Inc. has completed an IPO in the amount of $9.41775 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령